The FINGER trial: can lifestyle change the trajectory?

Plenty of studies show that healthy people get less dementia. The hard question is whether changing your behavior actually moves your own trajectory. The FINGER trial is the best attempt yet to answer that, and the answer is cautiously yes: over two years, a combined lifestyle program improved cognitive scores by about 25% on the overall test battery versus a control group. The part that matters most for you is the follow-up: APOE4 carriers benefited at least as much as everyone else.

What FINGER did

FINGER (the Finnish Geriatric Intervention Study to Prevent Cognitive Impairment and Disability) was a randomized controlled trial, the gold-standard design, in adults aged 60 to 77 who were already at risk of decline. For two years, one group got a multidomain intervention that combined four things at once:

• Nutritional guidance (a healthy, Mediterranean-style pattern)
• Physical exercise (aerobic and strength)
• Cognitive training
• Monitoring and management of vascular and metabolic risk factors

The control group got general health advice. The design is the point: it tested the whole package, not a single magic ingredient.

What it found

The intervention group’s cognitive scores improved over the two years while the control group stayed roughly flat, a gap of about 25% on the overall neuropsychological test battery (and larger on executive function and processing speed). It was modest but statistically significant, meaning it is unlikely to be chance, and the direction is what counts: the trained group got better, the control group did not. The headline is not any single component. It is that a combined, real-world lifestyle program can benefit cognition in at-risk older adults. FINGER moved dementia prevention from “plausible” toward “actionable.”

It helps to picture how intensive this was, because the dose is not a pamphlet. Participants did supervised gym sessions multiple times a week, structured cognitive-training sessions, regular dietitian visits, and nurse-led monitoring of blood pressure and metabolic markers, for two full years. Casual dabbling is not the same intervention.

The crucial APOE4 detail

For this audience, the most important result is the genotype follow-up. A prespecified analysis of APOE genotype (Solomon and colleagues, JAMA Neurology 2018), meaning it was planned in advance rather than fished out afterward, found that APOE4 carriers benefited from the intervention at least as much as non-carriers, and on some measures numerically more, with no sign that carrying ε4 blunted the response. The honest caveat is that the carrier subgroup was not large enough to prove carriers benefit more, only that they clearly benefit. Either way it directly counters the fatalistic “why bother, it’s genetic” story: in the best lifestyle-prevention trial we have, the people with the risk gene still gained.

Newer evidence pushes this further. A 2025 meta-analysis pooling three multidomain trials (FINGER plus the French MAPT and the Japanese J-MINT) tested the APOE-by-intervention question head-on, and found a statistically significant interaction (p = 0.035) pointing the other way from the fatalist’s intuition: ε4 carriers appeared to benefit more from the lifestyle program than non-carriers, consistently across European and Asian cohorts. This is pooled observational-within-trial evidence, not a single definitive RCT in carriers, so treat it as suggestive rather than settled. But the direction matters: the group with the most genetic risk may have the most to gain from doing the work.

A global movement

FINGER inspired World-Wide FINGERS, a network of similar trials adapting the model across different countries and populations. The biggest is the U.S. POINTER study (about 2,000 older adults at risk), which reported in 2025 that a structured multidomain lifestyle program improved global cognition over two years, with the structured and supervised version outperforming a self-guided one. POINTER matters because it replicates FINGER in a large, diverse US population, which strengthens the core message that the effect is not a Finnish fluke. Not every trial landed identically, though: MAPT, a French trial, had more mixed results, a fair reminder that the size and intensity of the program matter.

Why it matters for APOE4 carriers

• It supports the central premise of this site: the modifiable levers, pursued together, may meaningfully influence the trajectory, in line with the WHO’s emphasis on risk reduction.
• The intervention is essentially the package we cover throughout: diet, exercise, cognitive and social engagement, and vascular health, rather than a pill or a single hack.
• The genotype analysis says carriers are not excluded from the benefit. If anything, it is an argument to start.

The honest caveats

• FINGER measured cognitive performance over two years, not a lifetime of dementia outcomes. Longer trials are ongoing.
• Effects were at the group level, and individuals vary.
• The intervention was a supported, structured program. Doing it alone takes more intention.

What to actually do

You cannot replicate a research trial at home, but you can run its components. Build the same four levers into your week: a Mediterranean-style diet, regular exercise with both aerobic and strength work, cognitive and social engagement, and tight blood-pressure and metabolic control. Treat it as a structured habit, not occasional dabbling, ideally with a clinician’s input, since the dose mattered in the trial.

Common questions

Does FINGER prove lifestyle prevents Alzheimer’s? It proves a combined program can improve cognitive performance in at-risk older adults over two years. That is strong, actionable evidence, though not the same as a lifetime dementia-prevention guarantee.

Do the lifestyle changes work if I have the APOE4 gene? Yes. The prespecified genotype analysis found carriers benefited at least as much as non-carriers, which is exactly the point for this audience.

Do I need a formal program? The trial used a structured, supported one, which helps. But the components, diet, exercise, cognitive and social engagement, and vascular care, are all things you can start on your own, ideally with a clinician’s input.

The takeaway is empowering and well-grounded: a combined lifestyle program can support cognition in at-risk adults, carriers included. For carriers, that is the strongest kind of motivation, evidence that the levers you control are worth pulling, together and early. This is general education, not medical advice.